EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY-NC 4.0

CCR5 and CCL5 in metastatic colorectal cancer

Benjamin L Schlechter, Justin Stebbing iD

Journal for ImmunoTherapy of Cancer · 2024-05 · 12 (5) · e008722

DOI: 10.1136/jitc-2023-008722 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.05.2024. Verfasst von Benjamin L Schlechter und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Benjamin_Schlechter@DFCI.HARVARD.EDU. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Receptors, CCR5, Chemokine CCL5. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CCR/L5 axis is known for its role in immune regulation in a variety of settings and has been shown to have dichotomous functions in cancer, influencing both tumor progression and immune responses. Battaglin et al investigated its role using genomic and transcriptomic data from several datasets of patients with advanced colorectal cancer (CRC), including patients treated on CALGB/SWOG 80405, a trial of chemotherapy plus cetuximab versus bevacizumab, as well as a larger population of patients whose CRCs underwent commercially available Caris NGS and CODEai assays. These authors showed that CCR/L5 expression was both prognostic and predictive. They reported that low expression of the CCR/L5 axis was correlated with improved survival broadly, with particular benefit in patients treated with chemotherapy plus cetuximab. They demonstrated that high expression of CCR/L5 was associated with infiltration by negatively prognostic Tregs, M1 and M2 macrophages, myeloid-derived suppressor cells, and cancer-associated fibroblasts. They also showed that increased expression was correlated a wide variety of immune suppressive proteins, including PD-1, PD-L1, PD-L2, CTLA4, CD80, CD86, TIM3, IDO1, LAG3, and IFN-γ. This suggests mechanisms by which CRC resists anti-cancer immune responses. This study enhances our understanding of the role of the CCR/L5 axis in advanced CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsReceptors, CCR5Chemokine CCL5HumansNeoplasm Metastasis

Stichwörter der Autor:innen

Colon CancerCytokineImmune Checkpoint InhibitorTumor microenvironment - TME

Substanzen

Receptors, CCR5Chemokine CCL5CCR5 protein, humanCCL5 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Benjamin_Schlechter@DFCI.HARVARD.EDU.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Imperial College London, London, UK.

ORCID-Profile: Justin Stebbing

Zitieren

APA

Schlechter, B. L., & Stebbing, J. (2024). CCR5 and CCL5 in metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer, 12(5), e008722. https://doi.org/10.1136/jitc-2023-008722

Vancouver

Schlechter BL, Stebbing J. CCR5 and CCL5 in metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. 2024;12(5):e008722. doi:10.1136/jitc-2023-008722

BibTeX
@article{Schlechter2024,
  author = {Schlechter, Benjamin L and Stebbing, Justin},
  title = {CCR5 and CCL5 in metastatic colorectal cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {5},
  pages = {e008722},
  doi = {10.1136/jitc-2023-008722}
}
Kostenlos starten →